SCHEMBL14706397

SCHEMBL14706397

COc1cc(-c2nn(-c3cccc(N(C)C(=O)/C=C/CN4CCOCC4)c3)c3ncnc(N)c23)ccc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 10/20 0.44
▸ BTK Q06187 7/20 0.44
▸ EGFR P00533 5/20 0.44
▸ ITK Q08881 2/20 0.44
▸ JAK3 P52333 1/20 0.42
▸ SRC P12931 8/20 0.42
▸ PTK6 Q13882 7/20 0.41
▸ HCK P08631 4/20 0.41
▸ FYN P06241 4/20 0.41
▸ LYN P07948 3/20 0.41
▸ BLK P51451 3/20 0.41
▸ FRK P42685 2/20 0.41
▸ ABL1 P00519 6/20 0.40
▸ KIT P10721 2/20 0.40
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ PDGFRB P09619 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ CDK11B P21127 1/20 0.39
▸ CCNC P24863 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14706396 0.88 BTK (0.48) LCKBTKEGFRITKSRC
SCHEMBL14693537 0.86 BTK (0.45) LCKBTKEGFRSRCPTK6
SCHEMBL14693540 0.86 BTK (0.45) LCKBTKEGFRSRCPTK6
SCHEMBL14693485 0.85 BTK (0.45) BTKEGFRITKSRCPTK6
SCHEMBL14693483 0.85 BTK (0.45) BTKEGFRITKSRCPTK6
SCHEMBL14706394 0.84 SRC (0.46) LCKBTKEGFRITKJAK3
SCHEMBL14693583 0.80 BTK (0.43) LCKBTKEGFRITKSRC
SCHEMBL14693582 0.80 BTK (0.43) LCKBTKEGFRITKSRC
SCHEMBL15086970 0.79 FGFR1 (0.41) LCKBTKEGFRITKSRC
SCHEMBL14706392 0.79 SRC (0.45) LCKBTKEGFRITKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9546172-B2 Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS LLC (US) 2017-01-17 — — US disclosed
US-9546172-B2 Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS LLC (US) 2017-01-17 — — US disclosed
US-9273051-B2 Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS LLC (US) 2016-03-01 — — US disclosed
US-9273051-B2 Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS LLC (US) 2016-03-01 — — US disclosed
US-20130172314-A1 PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PHARMACYCLICS, INC. (US) 2013-07-04 — — US disclosed
US-20130172314-A1 PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS PHARMACYCLICS, INC. (US) 2013-07-04 — — US disclosed
US-8377946-B1 Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS, INC. (US) 2013-02-19 — — US disclosed
US-8377946-B1 Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors PHARMACYCLICS, INC. (US) 2013-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172314-A1 PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS BTK, LCK, LYN LCK 2/4885BTK 1/4885EGFR 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback